The DUSP7 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the DUSP7 gene in the A-549 human lung adenocarcinoma cell line. This polyclonal format provides a heterogeneous pool of cells with targeted DUSP7 disruption, enabling robust loss-of-function studies. DUSP7 encodes a dual-specificity phosphatase that negatively regulates mitogen-activated protein kinase (MAPK) signaling cascades.
The A-549 host cell line, derived from lung adenocarcinoma of a 58-year-old Caucasian male, displays alveolar type II-like epithelial characteristics. It is a widely adopted model for lung adenocarcinoma research, including studies of signal transduction, drug response, and tumorigenesis. The well-characterized genetic background and stable culture properties of A-549 cells make them particularly suited for CRISPR-mediated gene disruption.
DUSP7 functions as a dual-specificity phosphatase that dephosphorylates ERK1/2, JNK1/2, and p38 MAPK, attenuating signals initiated by receptor tyrosine kinases (e.g., EGFR), cytokines (e.g., TNF-alpha), and growth factors (e.g., EGF). The phosphatase interacts directly with ERK2, JNK1, and p38?? and operates within the RAS-RAF-MEK-ERK signaling axis to prevent ERK-mediated activation of transcription factors such as ELK1. This negative feedback loop restricts the amplitude and duration of MAPK pathway activity, thereby regulating cell proliferation, differentiation, and stress responses.
In A-549 cells, DUSP7 knockout eliminates dephosphorylation of MAPKs, leading to sustained phosphorylation and activation of ERK, JNK, and p38. This persistent signaling can enhance cell proliferation and survival while modulating apoptosis and stress responses, mirroring oncogenic pathway deregulation in lung adenocarcinoma. Consequently, this model is instrumental for studying MAPK negative feedback and evaluating the impact of phosphatase loss on tumor cell behavior.
Researchers can apply these polyclonal knockout cells to diverse experimental settings, including western blotting for phospho-ERK and phospho-JNK, RT-qPCR for DUSP7 expression, cell proliferation and apoptosis assays, and MAPK reporter systems. Key research applications include dissecting MAPK regulatory mechanisms, investigating lung cancer drug resistance, and exploring phosphatase function in oncogenesis. The DUSP7 Knockout A-549 Polyclonal Cells offer a versatile tool for signal transduction studies. For further information, please contact Ascent Research.
